Switching to duloxetine in selective serotonin reuptake inhibitor non- and partial-responders: Effects on painful physical symptoms of depression

Journal of Psychiatric Research

Volumn 43, Issue 5, 2009, Pages 512-518

  Perahia, David G S ^a,b   Quail, Deborah ^a   Desaiah, Durisala ^a   Montejo, Angel L ^c   Schatzberg, Alan F ^d  

^a ELI LILLY AND COMPANY   (United States)

^b Gordon Hospital   (United Kingdom)

^c HOSPITAL UNIVERSITARIO DE SALAMANCA   (Spain)

^d STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Depression; Duloxetine; Painful physical symptoms; Switch

Indexed keywords

CITALOPRAM; DULOXETINE; ESCITALOPRAM; FLUOXETINE; PAROXETINE; SEROTONIN UPTAKE INHIBITOR; SERTRALINE;

ADULT; ARTICLE; CLINICAL GLOBAL IMPRESSION SCALE; CONTROLLED STUDY; DAILY LIFE ACTIVITY; DEPRESSION; DISEASE SEVERITY; DRUG DOSE INCREASE; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG SAFETY; DRUG SUBSTITUTION; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEMALE; HAMILTON SCALE; HUMAN; MAJOR CLINICAL STUDY; MALE; PAIN; PAIN ASSESSMENT; PRIORITY JOURNAL; STRUCTURED QUESTIONNAIRE; VISUAL ANALOG SCALE;

EID: 59849094689     PISSN: 00223956     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jpsychires.2008.07.001     Document Type: Article

References (31)

1. Ahmed A., Schatzberg A.F., Friedman E.S., Rothschild A.J., Trivedi M.H., et al. Prevalence and clinical correlates of pain in patients with recurrent major depressive disorder. European Neuropsychopharmacology 17 (2007) S320-S321
2. Bair M.J., Robinson R.L., Katon W., and Kroenke K. Depression and pain comorbidity: a literature review. Archives of Internal Medicine 163 (2003) 2433-2445
3. Bauer M., Whybrow P.C., Angst J., Versiani M., Moller H.J., and World Federation of Societies of Biological Psychiatry Task Force on Treatment Guidelines for Unipolar Depressive Disorders. World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of unipolar depressive disorders, Part 1: Acute and continuation treatment of major depressive disorder. World Journal of Biological Psychiatry 3 (2002) 5-43
4. Brannan S.K., Mallinckrodt C.H., Brown E.B., Wohlreich M.M., Watkin J.G., and Schatzberg A.F. Duloxetine 60 mg once-daily in the treatment of painful physical symptoms in patients with major depressive disorder. Journal of Psychiatric Research 39 (2005) 43-53
5. DeLoach L.J., Higgins M.S., Caplan A.B., and Stiff J.L. The visual analog scale in the immediate postoperative period: intrasubject variability and correlation with a numeric scale. Anesthesia and Analgesia 86 (1998) 102-106
6. Demyttenaere K., Bonnewyn A., Bruffaerts R., Brugha T., De Graaf R., and Alonso J. Comorbid painful physical symptoms and depression: prevalence, work loss, and help seeking. Journal of Affective Disorders 92 (2006) 185-193
7. Detke M.J., Wiltse C.G., Mallinckrodt C.H., McNamara R.K., Demitrack M.A., and Bitter I. Duloxetine in the acute and long-term treatment of major depressive disorder: a placebo- and paroxetine-controlled trial. European Neuropsychopharmacology 14 (2004) 457-470
8. Fava M., Dunner D.L., Greist J.H., Preskorn S.H., Trivedi M.H., Zajecka J., et al. Efficacy and safety of mirtazapine in major depressive disorder patients after SSRI treatment failure: an open-label trial. Journal of Clinical Psychiatry 62 (2001) 413-420
9. Fava M, Mallinckrodt CH, Detke MJ, Watkin JG, Wohlreich MM. The effect of duloxetine on painful physical symptoms in depressed patients: do improvements in these symptoms result in higher remission rates? 2004. p. 521-30.
10. Fava M. Management of nonresponse and intolerance: switching strategies. Journal of Clinical Psychiatry 61 Suppl. 2 (2000) 10-12
11. Fava M., and Rush A.J. Current status of augmentation and combination treatments for major depressive disorder: a literature review and a proposal for a novel approach to improve practice. Psychotherapy and Psychosomatics 75 (2006) 139-153
12. Fields H.L., Heinricher M.M., and Mason P. Neurotransmitters in nociceptive modulatory circuits. Annual Review of Neuroscience 14 (1991) 219-245
13. Goldstein DJ, Lu Y, Detke MJ, Wiltse C, Mallinckrodt C, Demitrack MA. Duloxetine in the treatment of depression: a double-blind placebo-controlled comparison with paroxetine; 2004. p. 389-99.
14. Greco T., Eckert G., and Kroenke K. The outcome of physical symptoms with treatment of depression. Journal of General Internal Medicine 19 (2004) 813-818
15. Jones S.L. Descending noradrenergic influences on pain. Progress in Brain Research 88 (1991) 381-394
16. Judd L.L., Akiskal H.S., Maser J.D., Zeller P.J., Endicott J., and Coryell W. Major depressive disorder: a prospective study of residual subthreshold depressive symptoms as predictor of rapid relapse. Journal of Affective Disorders 50 (1998) 97-108
17. Karp J.F., Buysse D.J., Houck P.R., Cherry C., Kupfer D.J., and Frank E. Relationship of variability in residual symptoms with recurrence of major depressive disorder during maintenance treatment. American Journal of Psychiatry 161 (2004) 1877-1884
18. Kellner R. A symptom questionnaire. Journal of Clinical Psychiatry 48 (1987) 268-274
19. Kreider M.S., Bushnell W.D., Oakes R., and Wheadon D.E. A double-blind, randomized study to provide safety information on switching fluoxetine-treated patients to paroxetine without an intervening washout period. Journal of Clinical Psychiatry 56 (1995) 142-145
20. Kroenke K., Spitzer R.L., Williams J.B., Linzer M., Hahn S.R., deGruy F.V.I., et al. Physical symptoms in primary care. Predictors of psychiatric disorders and functional impairment. Archives of Family Medicine 3 (1994) 774-779
21. Ohayon M.M. Specific characteristics of the pain/depression association in the general population. Journal of Clinical Psychiatry 65 Suppl. 12 (2004) 5-9
22. Ohayon M.M., and Schatzberg A.F. Using chronic pain to predict depressive morbidity in the general population. Archives of General Psychiatry 60 (2003) 39-47
23. Perahia D.G., Pritchett Y.L., Desaiah D., and Raskin J. Efficacy of duloxetine in painful symptoms: an analgesic or antidepressant effect?. International Clinical Psychopharmacology 21 (2006) 311-317
24. Perahia D.G., Quail D., Desaiah D., Corruble E., and Fava M. Switching to duloxetine from selective serotonin reuptake inhibitor antidepressants: a multicenter trial comparing two switching techniques. Journal of Clinical Psychiatry 69 (2008) 95-105
25. Peselow E.D., Filippi A.M., Goodnick P., Barouche F., and Fieve R.R. The short- and long-term efficacy of paroxetine HCl: B. Data from a double-blind crossover study and from a year-long term trial vs. imipramine and placebo. Psychopharmacology Bulletin 25 (1989) 272-276
26. Rush A.J., Trivedi M.H., Wisniewski S.R., Stewart J.W., Nierenberg A.A., Thase M.E., et al. Bupropion-SR, sertraline, or venlafaxine-XR after failure of SSRIs for depression. New England Journal of Medicine 354 (2006) 1231-1242
27. Stahl S.M. The psychopharmacology of painful physical symptoms in depression. Journal of Clinical Psychiatry 63 (2002) 382-383
28. Thase M.E., Rush A.J., Howland R.H., Kornstein S.G., Kocsis J.H., Gelenberg A.J., et al. Double-blind switch study of imipramine or sertraline treatment of antidepressant-resistant chronic depression. Archives of General Psychiatry 59 (2002) 233-239
29. Ware J.E., Snow K.K., Kosinski M., and Gandek B. SF-36 health survey manual and interpretation guide (1993), The Health Institute, New England Medical Center, Boston, MA
30. Wise TN, Arnold LM, Maletic V. Management of painful physical symptoms associated with depression and mood disorders; 2005. p. 1-13.
31. Wise T.N., Fishbain D.A., and Holder-Perkins V. Painful physical symptoms in depression: a clinical challenge. Pain Medicine 8 Suppl. 2 (2007) S75-S82